OBA News

News from the NIH Office of Biotechnology Activities

February 14, 2011

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Preliminary Agenda for the March 8, 2011 RAC Meeting Now Available - The preliminary agenda for the March 8 meeting of the NIH Recombinant DNA Advisory Committee (RAC) is now available on the "RAC Meetings" page of the OBA Web site.

The RAC will review and discuss selected human gene transfer protocols including:

- A randomized Phase I/II trial using a GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine in combination with CCL21 for patients with Stage IV adenocarcinoma of the lung.

Also, the RAC will hear updates regarding two recently closed trials that used two different growth factors in patients with complications from peripheral vascular disease. These trials were:

- A randomized double-blind placebo-controlled parallel group study of the efficacy and safety of XRP0038/NV1FGF on amputation or any death in critical limb ischemia patients with skin lesions; and

- A Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-selection study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in patients with intermittent claudication.

The meeting will be held at the Bethesda Marriott, 6711 Democracy Blvd, Bethesda, MD 20817. All portions of the meeting are open to the public. **Please note that this meeting will not be webcast**; however, the meeting will be recorded and archived on the "RAC Meetings" page of the OBA Web site.

For more information, please contact Chezelle George, NIH Office of Biotechnology Activities, by email at georgec@mail.nih.gov or by telephone at 301-496-9838.